Gain Therapeutics, Inc. (GANX) AI Dilution Summary

Estimated cash was $11,669,856 as of 2026-08-07, rolled forward from $13,084,144 at 2026-06-30 against estimated monthly burn of $1,560,002. The company funds itself through its ATM program with Oppenheimer & Co. Inc., authorised to $50,000,000, which had sold 9,411,509 shares since the program began, through 2026-06-30; sales after 2026-06-30 are not yet reported.